Clinical Trial Detail

NCT ID NCT04493060
Title Niraparib and Dostarlimab for Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

pancreatic ductal adenocarcinoma

Therapies

Dostarlimab + Niraparib

Age Groups: adult senior

No variant requirements are available.